FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 315 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Trastuzumab Deruxtecan Shows Promising Activity Among Patients with HER2-positive and Signal... September 2, 2024 Dr Ian Walker on Smoking: ‘The killer behind the counter’ March 17, 2023 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... September 2, 2025 Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... September 10, 2021 Load more HOT NEWS PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... The award-winning researcher behind next generation sequencing Coronavirus and COVID-19: What People With Cancer Need to Know
